← All trials
NCT06902714
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 15, 2025
- Primary completion
- Jul 31, 2028
- Completion date
- Dec 31, 2030
- First posted
- Mar 30, 2025
- Last posted
- Oct 7, 2025
- Enrollment
- 60
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of Alabama, BirminghamLead sponsor
- University of Alabama, BirminghamSponsor investigator
- University of Alabama, BirminghamOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.